©The Author(s) 2023.
World J Hepatol. May 27, 2023; 15(5): 675-687
Published online May 27, 2023. doi: 10.4254/wjh.v15.i5.675
Published online May 27, 2023. doi: 10.4254/wjh.v15.i5.675
Table 3 Clinical Scoring Index for clinical probability of significant liver disease in hereditary hemorrhagic teleangiectasia patients[25]
| Criteria | Points | |
| Age at presentation (yr) | > 47 | 1 |
| ≤ 47 | 0 | |
| Sex | Female | 1 |
| Male | 0 | |
| Hb at presentation (g/dL) | < 8 | 3 |
| 8-12 | 2 | |
| 12-16 | 1 | |
| > 16 | 0 | |
| ALP at presentation (IU/L) | > 300 | 4 |
| 225-300 | 3 | |
| 150-224 | 2 | |
| 75-149 | 1 | |
| > 75 | 0 | |
| Clinical Scoring Index | Clinical probability of significant liver disease | |
| ≤ 2 | Low | (0.4%-3.2%) |
| 3-6 | Intermediate | (8.2%-64.1%) |
| ≥ 7 | High | (82.9%-93.0%) |
- Citation: Ielasi L, Tonnini M, Piscaglia F, Serio I. Current guidelines for diagnosis and management of hepatic involvement in hereditary hemorrhagic teleangiectasia. World J Hepatol 2023; 15(5): 675-687
- URL: https://www.wjgnet.com/1948-5182/full/v15/i5/675.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i5.675